IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that O3 ® Regional Oximetry has received FDA clearance for use on neonatal and infant patients (<10 kg). O3 may help clinicians ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results